RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Inhibitor Therapeutics Revenue 2024

Inhibitor Therapeutics Revenue

0 USD

Inhibitor Therapeutics Dividend yield

Ticker

INTI

ISIN

US45720M1053

WKN

A2PQRT

In 2024, Inhibitor Therapeutics's sales reached 0 USD, a 0% difference from the 0 USD sales recorded in the previous year.

The Inhibitor Therapeutics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2023--
2022--
2021--
2020--
2019--
2018--
2017--
2016--
2015--
2014--
2013--
2012--
2011--
2010--
20090.1860,00
20083.7223,12
20079.0317,50
20066.5316,69
20057.828,72
20045.7534,43

Inhibitor Therapeutics Aktienanalyse

What does Inhibitor Therapeutics do?

Inhibitor Therapeutics Inc is a biopharmaceutical company specializing in the development of innovative therapies for cancer and autoimmune diseases. The company was founded in the USA in 2008 and has since established itself as a leading player in the biotech industry. The history of Inhibitor Therapeutics Inc began with the discovery of a promising molecule called ITI-007, which could represent a novel treatment option for schizophrenia. After extensive preclinical tests and clinical studies, ITI-007 was eventually approved by the FDA and brought to market. The medication has proven to be very successful and is used by many patients worldwide. Today, Inhibitor Therapeutics Inc's business model includes several different divisions. In addition to schizophrenia therapy, the company focuses on the development of innovative cancer therapies based on the blockage of enzymes and proteins responsible for tumor growth. The company utilizes a wide range of technologies to develop the best therapies for different types of cancer. Inhibitor Therapeutics Inc's products also include a range of diagnostics and biomarkers that contribute to the early detection and treatment of cancer. These technologies enable personalized medicine and help improve the effectiveness of therapies. Overall, the goal of Inhibitor Therapeutics Inc is to improve the lives of millions of people through groundbreaking innovations in cancer and autoimmune therapy. The company works closely with leading scientific institutions and clinics to translate the latest research findings into clinical practice. An important part of Inhibitor Therapeutics Inc's corporate culture is promoting diversity and inclusion. The company actively strives to create a work environment that is open and inclusive, where every employee has the opportunity to reach their full potential. Overall, Inhibitor Therapeutics Inc is an emerging company specializing in the development of innovative therapies for cancer and autoimmune diseases. With a wide range of technologies and products, a strong corporate culture, and a dedicated team of employees, the company is well-positioned to continue growing in the coming years and make its vision of better health for all a reality. Inhibitor Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Inhibitor Therapeutics's Sales Figures

The sales figures of Inhibitor Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Inhibitor Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Inhibitor Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Inhibitor Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Inhibitor Therapeutics Stock

How much revenue did Inhibitor Therapeutics generate this year?

Inhibitor Therapeutics has achieved a revenue of 0 USD this year.

How much was the turnover of the company Inhibitor Therapeutics compared to the previous year?

The revenue of Inhibitor Therapeutics has increased by 0% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Inhibitor Therapeutics?

The revenue of Inhibitor Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Inhibitor Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Inhibitor Therapeutics so important for investors?

The revenue of Inhibitor Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Inhibitor Therapeutics pay?

Over the past 12 months, Inhibitor Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inhibitor Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Inhibitor Therapeutics?

The current dividend yield of Inhibitor Therapeutics is .

When does Inhibitor Therapeutics pay dividends?

Inhibitor Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Inhibitor Therapeutics?

Inhibitor Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Inhibitor Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Inhibitor Therapeutics located?

Inhibitor Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Inhibitor Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Inhibitor Therapeutics from 4/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/30/2024.

When did Inhibitor Therapeutics pay the last dividend?

The last dividend was paid out on 4/30/2024.

What was the dividend of Inhibitor Therapeutics in the year 2023?

In the year 2023, Inhibitor Therapeutics distributed 0 USD as dividends.

In which currency does Inhibitor Therapeutics pay out the dividend?

The dividends of Inhibitor Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Inhibitor Therapeutics

Our stock analysis for Inhibitor Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inhibitor Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.